Naltrexone/Bupropion Cardiovascular Outcomes Study
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone
hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo
and rule out excess risk of major adverse cardiovascular events (MACE) when given in
combination with standard of care in overweight and obese participants with documented
history of CV disease.